Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Identification of human leukocyte antigen (HLA)-restricted cytotoxic T lymphocyte (CTL) epitopes is important for understanding the immunity in viral or bacterial infections, autoimmune diseases, and cancer as well as for the development of defined vaccines. Creative Biolabs provides high-quality HLA competition assays to identify peptides binding to HLA molecules.
The peptide-binding groove of HLA molecules contains highly polymorphic allele-specific pockets that accommodate side chains of the so-called anchor residues of the bound peptide. The HLA competition assay aims at identifying peptides that bind to a wide range of HLA molecules. The methods are capable of predicting the binding of any given peptide to any given HLA molecule.
HLA class I competition assay can be used in a screening procedure for identifying peptides binding to HLA molecules. It includes a titration procedure for determining the affinity of the positive peptides from the screening. Creative Biolabs uses a conformation-dependent anti-HLA class I antibody as one tag and a biotinylated recombinant HLA class I molecule as the other tag, and a proximity-based signal is generated through the luminescent oxygen channeling immunoassay technology. Compared with an enzyme-linked immunosorbent assay (ELISA) -based peptide-HLA class I binding assay, this assay yields virtually identical affinity measurements, with lots of features, such as a broader dynamic range, better signal-to-background ratios, and a higher capacity.
HLA class II competition assay may be used to measure the affinity of putative epitopes for multiple HLA alleles. Our assay employs highly-purified class II molecules. Based on a concentration peptide titration, this assay format is far superior in sensitivity and specificity compared to cell-based assay formats. A non-linear regression analysis will be performed and an IC50 value will be calculated.
Fig.1 Workflow of HLA class I competition assay.
Our HLA competition assay can be adapted to accommodate a range of requirements:
As a reliable partner in HLA Testing, Creative Biolabs aspires to become the best solution provider for our clients. Except for HLA testing service, Creative Biolabs also provides a full range of HLA-related products. For more information, please send us an inquiry or contact us directly.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
